Inhibikase Therapeutics, Inc. (IKT)

NASDAQ: IKT · Real-Time Price · USD

2.310

0.00 (0.00%)

At close: Sep 16, 2026, 4:00 PM EDT

2.320

+0.010 (0.43%)

After-hours: Sep 16, 2026, 7:30 PM EDT

Inhibikase Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	31.21	139.22	56.49	9.17	7.19	40.75
Short-Term Investments	127.81	39.54	41.05	4.09	15.86	-
Cash & Short-Term Investments	159.02	178.76	97.54	13.25	23.05	40.75
Cash Growth	81.39%	83.27%	636.06%	-42.51%	-43.44%	192.04%
Receivables	-	-	-	-	0.04	0.11
Prepaid Expenses	0.91	0.32	0.83	0.74	0.16	1.5
Other Current Assets	2.42	1.03	0.08	0.22	1.12	0.11
Total Current Assets	162.34	180.11	98.45	14.21	24.37	42.47
Property, Plant & Equipment	-	-	0.15	0.3	0.57	-
Other Long-Term Assets	1.24	1.1	-	-	-	-
Total Assets	163.59	181.2	98.6	14.51	24.94	42.47

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Accounts Payable	0.99	1.16	0.94	0.65	1.15	1.09
Accrued Expenses	9.27	4.08	2.68	2.26	2.4	2.72
Short-Term Debt	-	-	-	0.38	-	-
Current Portion of Long-Term Debt	-	-	-	-	-	0.25
Current Portion of Leases	-	-	0.11	0.15	0.15	-
Other Current Liabilities	-	3.06	-	-	-	-
Total Current Liabilities	10.26	8.3	3.73	3.44	3.7	4.05
Long-Term Leases	-	-	-	0.09	0.21	-
Total Liabilities	10.26	8.3	3.73	3.53	3.9	4.05

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Common Stock	0.13	0.13	0.07	0.01	0	0.03
Additional Paid-In Capital	331.92	315.43	189.25	77.87	68.8	68.21
Retained Earnings	-178.65	-142.68	-94.42	-66.9	-47.87	-29.82
Comprehensive Income & Other	-0.07	0.02	-0.04	0	0.1	-
Shareholders' Equity	153.33	172.9	94.87	10.98	21.04	38.42
Total Liabilities & Equity	163.59	181.2	98.6	14.51	24.94	42.47

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Total Debt	-	-	0.11	0.62	0.35	0.25
Net Cash (Debt)	159.02	178.76	97.43	12.63	22.7	40.5
Net Cash Growth	81.47%	83.47%	671.44%	-44.36%	-43.95%	197.05%
Net Cash Per Share	1.13	1.82	4.11	2.10	5.37	13.35
Filing Date Shares Outstanding	182.07	170.42	90.01	6.48	4.83	4.2
Total Common Shares Outstanding	174.57	170.08	89.18	6.19	4.2	4.19
Working Capital	152.08	171.81	94.72	10.77	20.68	38.42
Book Value Per Share	0.88	1.02	1.06	1.77	5.00	9.16
Tangible Book Value	153.33	172.9	94.87	10.98	21.04	38.42
Tangible Book Value Per Share	0.88	1.02	1.06	1.77	5.00	9.16
Machinery	-	-	0.1	0.1	0.24	-

SEC Filings: 10-K · 10-Q